Top 10 Undervalued Stocks To Buy Right Now

tags:DNP,FDI,PGNX,GSV,BYDDY,AEMD,CDTI,PRTA,CLMT,APHQF,

Employing contrarian investing tactics is exceptionally difficult. Evolutionarily speaking, we are inclined to follow the majority and not stray from the pack. However, in investing, it can be extraordinarily lucrative to deviate from the consensus. The consensus view of Bed Bath & Beyond (NASDAQ:BBBY) is that the company faces several headwinds that will stagnate growth and cause the stock price to languish. Nonetheless, the market is overly discounting shares of BBBY and is providing an undervalued opportunity.

"Be fearful when others are greedy and greedy when others are fearful." - Warren Buffett

Top 10 Undervalued Stocks To Buy Right Now: Duff & Phelps Utilities Income, Inc.(DNP)

Advisors' Opinion:

• [By Shane Hupp]

  Stratos Wealth Partners LTD. lifted its holdings in DNP Select Income Fund Inc. Common Stock (NYSE:DNP) by 108.1% during the first quarter, Holdings Channel reports. The institutional investor owned 17,485 shares of the investment management company’s stock after purchasing an additional 9,084 shares during the period. Stratos Wealth Partners LTD.’s holdings in DNP Select Income Fund Inc. Common Stock were worth $180,000 as of its most recent filing with the SEC.

Top 10 Undervalued Stocks To Buy Right Now: Fort Dearborn Income Securities, Inc.(FDI)

Advisors' Opinion:

• [By Ethan Ryder]

  Press coverage about Fort Dearborn Income Securities (NYSE:FDI) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fort Dearborn Income Securities earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the investment management company an impact score of 47.5421964561374 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Top 10 Undervalued Stocks To Buy Right Now: Progenics Pharmaceuticals Inc.(PGNX)

Advisors' Opinion:

• [By Ethan Ryder]

  Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) saw unusually large options trading on Monday. Investors purchased 10,312 call options on the company. This represents an increase of approximately 2,171% compared to the average daily volume of 454 call options.

• [By Brian Orelli]

  Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) are down 16.8% at 12:07 p.m. EDT after releasing disappointing top-line data for the phase 3 clinical trial testing its prostate cancer imaging agent, dubbed 1404. While the test proved specific enough, it didn't meet the study's other endpoint of sensitivity.

• [By Cory Renauer]

  Here's what you need to know about the catalysts that could send these stocks soaring, or plummeting, in the third quarter.

  Company Market Cap Incoming Catalyst Spark Therapeutics Inc. (NASDAQ:ONCE)  $3.09 billion Clinical trial results Zogenix, Inc. (NASDAQ:ZGNX) $1.56 billion Clinical trial results Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) $593 million PDUFA date

  Data source: Yahoo! Finance.

• [By Keith Speights]

  Neurocrine Biosciences (NASDAQ:NBIX), along with partner AbbVie (NYSE:ABBV), Progenics Pharmaceuticals (NASDAQ:PGNX), and Insys Pharmaceuticals (NASDAQ:INSY) await major approval decisions by the U.S. Food and Drug Administration (FDA). Here's what you need to know about the potential catalysts for these biotech stocks.

• [By Chris Lange]

  Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) shares dropped sharply on Thursday after the company announced late-stage results from its prostate cancer study. Specifically, the firm announced top-line data from its Phase 3 study of 1404, its prostate specific membrane antigen-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer.

Top 10 Undervalued Stocks To Buy Right Now: Gold Standard Ventures Corporation(GSV)

Advisors' Opinion:

• [By Ethan Ryder]

  Gold Standard Ventures Corp (NYSEAMERICAN:GSV) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 6,511,796 shares, a drop of 7.7% from the April 30th total of 7,056,069 shares. Based on an average daily volume of 268,131 shares, the short-interest ratio is currently 24.3 days. Approximately 5.9% of the company’s stock are sold short.

Top 10 Undervalued Stocks To Buy Right Now: BYD Company Limited (BYDDY)

Advisors' Opinion:

• [By ]

  Chinese electric-car startup NIO (formerly known as NextEV), which has attracted three of China's famous BATX tech giants, namely, Baidu (BIDU), Tencent (OTCPK:TCEHY) (OTCPK:TCTZF), and Xiaomi (XI) as investors, is also based in Shanghai. Singapore's state investment vehicle Temasek Holdings and computing titan Lenovo Group (OTCPK:LNVGY) (OTCPK:LNVGF) are also early backers of NIO. Qoros Automotive, a 50-50 joint venture between Chinese state-owned Chery Automobile and Singaporean investment company Kenon Holdings, is headquartered in Shanghai, while its assembly plant in Changshu is near Shanghai. Looking elsewhere in China, BYD Co. Ltd. (OTCPK:BYDDF) (OTCPK:BYDDY), a Chinese EV-maker backed by Warren Buffett's Berkshire Hathaway (BRK.A) (BRK.B), has manufacturing sites in Shenzhen, Huizhou, Shanxi, and Shanghai.

• [By ]

  BYD Co., Ltd. (OTCPK:BYDDY) (OTCPK:BYDDF) is the world's largest manufacturer of EVs (electric vehicles). It is also a major player in e-buses, e-trucks, solar panels, energy storage and batteries. In addition, last year it launched its "Skyrail" transit system. Founder and chairman Wang Chuanfu surprised the markets when he previously announced a planned ten-fold increase in revenues by 2025.

• [By ]

  Current subsidies in China were reduced by 20% in 2017 and will be reduced by 40% in 2019 and 100% by 2021. China's Zero Emission Vehicle (ZEV) credit system was announced on September 28, 2017, and will begin in 2019 with 10% of credits (12% in 2020) required from new energy vehicles (NEVs). That translates to ~4-5% of EV sales as market share for 2019. We also are expecting an announcement at some stage as to when China will ban ICE vehicles, noting BYD (OTCPK:BYDDY) Chairman Wang thinks by 2030. Others think it will be 2035.

• [By ]

  The pace of consolidations of Chinese rechargeable battery cell companies is accelerating. We made an assertion in our previous report that, with a few exceptions (CATL, BYD), most Chinese names would be consolidated due to the change of subsidy policy by Beijing, and that the industry is likely to become more oligopolistic. It appears that this trend is becoming more pronounced. According to SNE Research, the combined market share of CATL and BYD in the Chinese EV battery market has grown from 43.9% in 2017 to 63.6% in 1H18. China's subsidies are mostly for high- performance rechargeable batteries, and the NEV credit system, which was implemented this year, is designed to give more credits to companies that use high-performance rechargeable batteries. As such, high-end rechargeable batteries are likely to drive demand, but realistically only CATL and BYD (OTCPK:BYDDY) have the capacity to make these batteries in China.

• [By ]

  Source

  2016 August 2016 - EV monthly news begins. The world's first self-driving taxi service was launched in Singapore, with human drivers as backup. Bloomberg wrote "Why Electric Cars Will Be Here Sooner Than You Think" , and I wrote "Electric Vehicles Will Be Affordable And Popular By 2020 - An EV Portfolio To Consider." BYD Co's (OTCPK:BYDDF) (OTCPK:BYDDY) global bus and taxi expansion continues. BYD enters into the monorail business. BYD ends 2016 as global No 1 electric car seller yet again. Lithium saw its price triple in 2016. Global EV sales finished 2016 at 774,000 for the year, up 40% on 2015, and representing 0.85% of the global market share.

  EV costs declining graph

• [By ]

  BYD Co. (OTCPK:BYDDY), (OTCPK:OTCPK:BYDDF) HK:1211

  BYD is currently ranked the number 2 globally with 9% global market share, and is ranked number 1 in China with 24% market share.

Top 10 Undervalued Stocks To Buy Right Now: Aethlon Medical, Inc.(AEMD)

Advisors' Opinion:

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Aethlon Medical (AEMD)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Shane Hupp]

  Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it contrast to its rivals? We will compare Aethlon Medical to similar businesses based on the strength of its analyst recommendations, valuation, dividends, institutional ownership, risk, earnings and profitability.

• [By Money Morning Staff Reports]

  But before we show you our pick, here are the top 10 penny stocks to watch this week…

  Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5) My Size Inc. (Nasdaq: MYSZ) $1.66 152.28% Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52% DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02% CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71% China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58% Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12% Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01% Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5% Cenveo Inc. (Nasdaq: CVO) $1.20 31.82% EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%

  
  FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it's completely free…

• [By Max Byerly]

  Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare Aethlon Medical to related companies based on the strength of its analyst recommendations, valuation, earnings, profitability, institutional ownership, dividends and risk.

• [By Shane Hupp]

  ValuEngine upgraded shares of Aethlon Medical (NASDAQ:AEMD) from a hold rating to a buy rating in a research report released on Monday.

  Separately, HC Wainwright set a $3.00 price objective on Aethlon Medical and gave the company a buy rating in a research report on Monday.

Top 10 Undervalued Stocks To Buy Right Now: Clean Diesel Technologies Inc.(CDTI)

Advisors' Opinion:

• [By Logan Wallace]

  Shares of CDTi Advanced Materials Inc (NASDAQ:CDTI) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $0.33 and last traded at $0.36, with a volume of 500 shares trading hands. The stock had previously closed at $0.36.

• [By Stephan Byrd]

  Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

  Get Molecular Templates alerts: Trading Center: Watching the Levels for Molecular Templates, Inc. (:MTEM): Move of 0.02 Since the Open (stocknewscaller.com) Molecular Templates (MTEM) Announces Clinical Data at 2018 ASCO Meeting (streetinsider.com) Gallbladder Cancer Treatment Sales Market Size by Players, Regions, Type, Application and Forecast to 2025 (exclusivereportage.com) ATR in spotlight EnSync, Inc. (NYSE:ESNC), CDTi Advanced Materials, Inc. (NASDAQ:CDTI), Molecular Templates, Inc … (stocksnewspoint.com)

  MTEM has been the subject of several research analyst reports. ValuEngine lowered shares of Molecular Templates from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Zacks Investment Research raised shares of Molecular Templates from a “sell” rating to a “hold” rating in a research report on Thursday, June 7th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $5.20.

Top 10 Undervalued Stocks To Buy Right Now: Prothena Corporation plc(PRTA)

Advisors' Opinion:

• [By Brian Feroldi]

  In response to announcing that it is stopping all clinical development of its lead product candidate, Prothena (NASDAQ:PRTA), a clinical-stage biotech focused on neuroscience and orphan diseases, saw its shares fall 69% as of 11 a.m. EDT.

• [By Cory Renauer]

  April's been a month of biotech bloodbaths. In a 15-day span, Incyte Corporation (NASDAQ:INCY), Prothena Corporation PLC (NASDAQ:PRTA), and Celldex Therapeutics Inc. (NASDAQ:CLDX) have all reported clinical trial failures that have hammered their stock prices.

• [By Lisa Levin]

  Prothena Corporation plc (NASDAQ: PRTA) shares dropped 69 percent to $11.43 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.

• [By Lisa Levin]

  Check out these big penny stock gainers and losers

  Losers Prothena Corporation plc (NASDAQ: PRTA) shares dipped 69 percent to $11.48 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Gridsum Holding Inc. (NASDAQ: GSUM) fell 44.3 percent to $4.06. Gridsum reported suspension of audit report on financial statements. Flotek Industries, Inc. (NYSE: FTK) shares declined 34.1 percent to $4.16 as the company issued weak revenue forecast for the first quarter. Akorn, Inc. (NASDAQ: AKRX) dropped 32.3 percent to $13.35 after Fresenius terminated its merger deal with Akorn. Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 31.2 percent to $13.44. Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron. Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS) dropped 18 percent to $5.76. Controladora Vuela recently reported first-quarter results that showed a loss for the quarter. Imperial Capital downgraded Controladora Vuela Compania de Aviacion from Outperform to In-Line. Atossa Genetics Inc. (NASDAQ: ATOS) fell 18.2 percent to $2.8797 after declining 19.35 percent on Friday. Alcoa Corporation (NYSE: AA) fell 12.3 percent to $52.63. Luby's, Inc. (NYSE: LUB) shares declined 10.3 percent to $2.448 following Q2 results. Aceto Corporation (NASDAQ: ACET) shares tumbled 10 percent to $2.26. Pier 1 Imports, Inc. (NYSE: PIR) dipped 9.7 percent
• [By Lisa Levin]

  Prothena Corporation plc (NASDAQ: PRTA) shares dropped 69 percent to $11.585 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.

• [By Max Byerly]

  Royal Bank of Canada reduced its stake in Prothena Co. PLC (NASDAQ:PRTA) by 40.0% during the first quarter, Holdings Channel reports. The fund owned 7,337 shares of the biotechnology company’s stock after selling 4,888 shares during the period. Royal Bank of Canada’s holdings in Prothena were worth $269,000 as of its most recent SEC filing.

Top 10 Undervalued Stocks To Buy Right Now: Calumet Specialty Products Partners L.P.(CLMT)

Advisors' Opinion:

• [By Stephan Byrd]

  Calumet Specialty Products Partners (NASDAQ:CLMT) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Saturday.

• [By Max Byerly]

  Get a free copy of the Zacks research report on Calumet Specialty Products Partners, L.P (CLMT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Tyler Crowe]

  Whenever a company is in the midst of a multiyear turnaround plan like Calumet Specialty Products Partners (NASDAQ:CLMT), some quarters are going to show more progress than others. This past quarter was one of those less noticeable quarters as many of the moves it made were a detriment to the bottom line. Nevertheless, there were some reasons investors should be satisfied with what Calumet did in the quarter.

• [By Reuben Gregg Brewer]

  Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) is attempting to shift gears as it refocuses around higher-margin refined chemicals products. The plan sounds good on paper, and the independent refiner appears to be making progress. However, after a doubling of the price over the past year, most investors need to think carefully before jumping on this bandwagon. Here's why.

• [By Reuben Gregg Brewer]

  Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) and Delek US Holdings, Inc. (NYSE:DL) have both witnessed large stock advances over the past year. However, the performances of these chemical and refining companies have started to diverge somewhat over the past few months. There's a good reason for this, but does that make Delek, the better performer this year, the better stock for investors?

Top 10 Undervalued Stocks To Buy Right Now: Aphria Inc. (APHQF)

Advisors' Opinion:

• [By Todd Campbell]

  For now, the Constellation Brands deal gives Canopy Growth a big advantage over its Canadian competitors, but I wouldn't count those peers out yet. There's a chance that other companies, fearful of being left out of the market, come calling on Canada's other big marijuana companies. If so, Aurora Cannabis (NASDAQOTH:ACBFF) and Aphria (NASDAQOTH:APHQF) could be worth watching.

• [By Keith Speights]

  The second-place prize goes to Aphria (NASDAQOTH:APHQF). The Canadian marijuana grower's share price has soared over 1,900% since 2015. Like Canopy Growth, Aphria got its start supplying medical cannabis in Canada and is now gearing up for the country's recreational marijuana market.

• [By Sean Williams]

  In late May, Aphria (NASDAQOTH:APHQF) announced that it was forming a new venture known as CannInvest Africa that's designed to supply cannabis extracts to legalized African countries, as well as the one dozen countries currently in Aphria's supply network. This venture came about from a roughly $3 million investment with the Verve Group of Companies. Aphria's management team fully understands the need to broaden the company's horizons to sell what could be a lot of excess cannabis in Canada's domestic market. 

• [By Sean Williams]

  On June 6, 2018, Aphria (NASDAQOTH:APHQF) announced a bought-deal financing that'll see nearly 19 million shares of common stock sold for $11.85 Canadian dollars ($9.13 U.S. dollars) per share. An underwriters' option exists as well that could allow for an additional 2.84 million shares to be purchased. Without the underwriters' option, this is a CA$225 million offering ($173.3 million). Including the underwriters' option, assuming it's exercised, this is a CA$258.8 million offering ($199.4 million). Either way, it represents the largest bought-deal financing in history, eclipsing the approximately CA$200 million bought-deal financings from Aurora Cannabis and Canopy Growth Corp. 

• [By Keith Speights]

  Still, legalization of recreational marijuana in Canada is closer than ever to becoming a reality. Although it didn't look like any marijuana growers that were big winners from the Thursday vote, appearances can be deceiving. Three stocks, in particular, should enjoy nice gains once the dust settles: Canopy Growth (NYSE:CGC), Aurora Cannabis (NASDAQOTH:ACBFF), and Aphria (NASDAQOTH:APHQF). 

• [By Cory Renauer]

  The North American Marijuana Index, which tracks the leading cannabis stocks in the U.S. and Canada, is right about where it was to start the year despite surging over the past few months of 2017. The same could be said for one of Canada's larger growers. Aphria (NASDAQOTH:APHQF) stock has risen in recent weeks, but it's still a bit below a peak it achieved in January.